Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

Philippe Rousselot; Aude Charbonnier; Pascale Cony-Makhoul; Philippe Agape; Franck E Nicolini; Bruno Varet; Martine Gardembas; Gabriel Etienne; Delphine Réa; Lydia Roy; Martine Escoffre-Barbe; Agnès Guerci-Bresler; Michel Tulliez; Stéphane Prost; Marc Spentchian; Jean Michel Cayuela; Josy Reiffers; Jean Claude Chomel; Ali Turhan; Jo?lle Guilhot; Fran?ois Guilhot; Fran?ois-Xavier Mahon

首页> 外文期刊>Journal of Clinical Oncology >Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

【24h】

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

机译：在持续性无法检测的疾病后已停止伊马替尼治疗的慢性期慢性粒细胞白血病患者中，主要分子反应的丧失是重新开始酪氨酸激酶抑制剂治疗的触发因素。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Loss of MMR is a practical and safe criterion for restarting therapy in patients with CML with prolonged CMR.

机译：MMR的丢失是对于CMR延长的CML患者重新开始治疗的实用且安全的标准。

著录项

来源
《Journal of Clinical Oncology》 |2014年第5期|共7页
作者
Philippe Rousselot; Aude Charbonnier; Pascale Cony-Makhoul; Philippe Agape; Franck E Nicolini; Bruno Varet; Martine Gardembas; Gabriel Etienne; Delphine Réa; Lydia Roy; Martine Escoffre-Barbe; Agnès Guerci-Bresler; Michel Tulliez; Stéphane Prost; Marc Spentchian; Jean Michel Cayuela; Josy Reiffers; Jean Claude Chomel; Ali Turhan; Jo?lle Guilhot; Fran?ois Guilhot; Fran?ois-Xavier Mahon;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. [J] . Philippe Rousselot, Aude Charbonnier, Pascale Cony-Makhoul, Journal of Clinical Oncology . 2014,第5期

机译：在持续性无法检测的疾病后已停止伊马替尼治疗的慢性期慢性粒细胞白血病患者中，主要分子反应的丧失是重新开始酪氨酸激酶抑制剂治疗的触发因素。
2. Cessation of tyrosine kinase inhibitors in patients with chronic-phase chronic myelogenous leukemia following durable complete molecular response: A single center facing the dilemma [J] . IliakisT., PapadopoulouV., DiamantopoulosP.T., Anticancer Research: International Journal of Cancer Research and Treatment . 2013,第8期

机译：持久性完全分子应答后慢性期慢性粒细胞性白血病患者中酪氨酸激酶抑制剂的终止：一个面临困境的中心
3. Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Interim Results of Russian Prospective Multicenter Trial RU-SKI [J] . Petrova Anna, Chelysheva Ekaterina, Shukhov Oleg, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：慢性骨髓白血病患者的生活质量深沉的分子反应，酪氨酸激酶抑制剂停止治疗：俄罗斯前瞻性多中心试验Ru-Ski的中期结果
4. Combination effects of repetitive pulsed magnetic stimulation and tyrosine kinase inhibitor imatinib for chronic myeloid leukemia cell line TCC-S [C] . S. Yamaguchi, M. Sekino, Y. Sato, Intermag Conference . 2006

机译：重复脉冲磁刺激和酪氨酸激酶抑制剂慢性髓性白血病细胞系TCC-S的组合效应
5. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy [O] . Masayuki Shiseki, Chikashi Yoshida, Naoki Takezako, -1

机译：达沙替尼可快速诱导慢性阶段性髓样白血病患者的深层分子反应这些患者通过伊马替尼治疗可达到可检测水平的BCR-ABL1转录本从而达到主要分子反应
6. Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: Study by the Nagasaki CML Study Group [O] . Itonaga Hidehiro, Tsushima Hideki, Imanishi Daisuke, 2014

机译：在实践中用酪氨酸激酶抑制剂治疗的慢性髓性白血病中BCR-aBL1激酶结构域的分子分析：长崎CmL研究组的研究

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

摘要

著录项

相似文献

相关主题

期刊订阅